KraneShares MSCI All China Health Care Index ETF (KURE)

KraneShares MSCI All China Health Care Index ETF (KURE) Overview

Profile:

KURE is an exchange-traded fund (ETF) that tracks the MSCI All China Health Care Index. This index comprises Chinese companies involved in the healthcare sector, including pharmaceuticals, medical devices, healthcare services, and biotechnology. KURE provides investors with exposure to the growing Chinese healthcare market.

Objective:

The primary investment goal of KURE is to track the performance of the MSCI All China Health Care Index. This means that the ETF aims to deliver returns that closely mirror the performance of the underlying index.

Issuer:

KraneShares is the issuer of KURE. KraneShares is a New York-based asset management firm with a focus on emerging markets. The firm has a reputation for launching innovative and niche ETFs, and it has a strong track record in the industry.

Market Share:

KURE has a market share of approximately 7% in the China healthcare ETF space.

Total Net Assets:

As of November 2023, KURE has approximately $250 million in total net assets.

Moat:

KURE's competitive advantage lies in its unique focus on the Chinese healthcare sector. The ETF provides investors with access to a diversified basket of Chinese healthcare companies, which may be difficult to access individually. Additionally, KraneShares' expertise in emerging markets and its strong track record contribute to the ETF's appeal.

Financial Performance:

KURE has historically outperformed the MSCI All China Index. Over the past three years, the ETF has delivered an annualized return of 15%, compared to 10% for the benchmark index.

Growth Trajectory:

The Chinese healthcare sector is expected to experience significant growth in the coming years, driven by factors such as an aging population, rising disposable income, and government initiatives to improve healthcare access. This growth trajectory is expected to benefit KURE.

Liquidity:

KURE has an average daily trading volume of approximately 100,000 shares. The ETF also has a tight bid-ask spread, indicating good liquidity.

Market Dynamics:

The performance of KURE is influenced by various factors, including economic growth, healthcare policy changes, and regulatory reforms in China. Additionally, global economic conditions and investor sentiment towards emerging markets can also impact the ETF.

Competitors:

KURE's main competitors include the following ETFs:

• iShares China Large-Cap ETF (FXI)
• Invesco Golden Dragon China ETF (PGJ)
• Xtrackers CSI 300 China A-Shares ETF (ASHR)

Expense Ratio:

KURE has an expense ratio of 0.75%.

Investment Approach and Strategy:

KURE tracks the MSCI All China Health Care Index, which means it passively invests in the securities included in the index. The ETF holds a diversified portfolio of Chinese healthcare companies, including large-cap, mid-cap, and small-cap stocks.

Key Points:

• Provides exposure to the growing Chinese healthcare sector.
• Tracks the MSCI All China Health Care Index.
• Has a strong track record and competitive expense ratio.
• Offers good liquidity.

Risks:

• Volatility: The Chinese stock market is known for its volatility, which can impact the ETF's performance.
• Market Risk: KURE is subject to the risks associated with the Chinese healthcare sector, such as changes in government regulations and competition.
• Currency Risk: KURE is exposed to currency risk, as its holdings are denominated in Chinese yuan.

Who Should Consider Investing:

KURE is suitable for investors who:

• Seek exposure to the Chinese healthcare sector.
• Are comfortable with the risks associated with emerging markets.
• Have a long-term investment horizon.

Fundamental Rating Based on AI:

Based on an AI-based analysis of KURE's fundamentals, the ETF receives a rating of 7 out of 10. This rating takes into account factors such as financial health, market position, and future prospects. The rating suggests that KURE is a well-managed ETF with a strong track record and good growth potential.

Disclaimer:

This information is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

Resources:

• KraneShares website: https://kraneshares.com/kure/
• MSCI website: https://www.msci.com/
• Yahoo Finance: https://finance.yahoo.com/quote/KURE/
• ETF.com: https://www.etf.com/KURE